No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis - 10/10/20
Funding sources: Supported by Eli Lilly and Company (Indianapolis, IN, USA), which sponsored this study and provided medical writing (Elinor Wylde and Deirdre Elmhirst, Rx Communications) for this correspondence. |
|
Disclosure: Dr Mrowietz has been an advisor and/or received speaker honoraria and/or received grants and/or contributed to clinical trials for the following companies: AbbVie, Almirall, Aristea, Boehringer Ingelheim, Celgene, Dr Reddy's, Eli Lilly, Foamix, Formycon, Forward Pharma, Janssen, Leo Pharma, Medac, Novartis, UCB, and Xenoport. Drs Riedl, Xu, Patel, and Agada are employees of Eli Lilly and Company. Dr Lebwohl is an employee of Mount Sinai who receives research funds from the following companies: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Kadmon, Leo Pharma, MedImmune, Novartis, Ortho Dermatologics, Pfizer, SciDerm, UCB, and Vidac and is a consultant for Allergan, Almirall, Arcutis, Avotres, Birch BioMed, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, Leo Pharma, Meiji, Menlo, Mitsubishi Pharma, NeuroDerm Ltd, Pfizer, Promius/Dr Reddy's, Theravance Biopharma, and Verrica. Dr Winkler has no conflicts of interest to declare. |
|
IRB approval status: N/A. |
|
Reprints not available from the authors. |
Vol 83 - N° 5
P. 1436-1439 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?